New blood test offers early warning for liver cirrhosis risk

A novel blood test shows promise in detecting individuals vulnerable to liver cirrhosis, potentially enabling earlier intervention before the condition progresses to failure or cancer. The development addresses a significant public health challenge in the region, where liver disease remains endemic due to hepatitis B infection, alcohol consumption, and metabolic disorders.

Liver cirrhosis claimed approximately 1.43 million lives globally in 2021, according to recent mortality data. The disease develops silently in many patients, often going undetected until irreversible damage has occurred. Early identification of at-risk individuals could allow healthcare providers to implement preventive measures and monitor disease progression more closely.

The blood test works by identifying biomarkers associated with liver fibrosis and cirrhosis risk. By detecting these markers before clinical symptoms manifest, the test may help clinicians intervene at earlier, more treatable stages of liver disease. This is particularly relevant for patients with chronic hepatitis, fatty liver disease, or other underlying conditions that predispose them to cirrhosis.

Hepatologists across South and Southeast Asia have expressed interest in the diagnostic advance, given the high prevalence of liver disease in the region. Healthcare systems are evaluating how such tests might be integrated into screening programmes and routine clinical practice. Further validation studies are underway to confirm the test's accuracy and utility in diverse patient populations.